Anti-angiogenesis effect of 3′-sulfoquinovosyl-1′-monoacylglycerol via upregulation of thrombospondin 1

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1546-1552

  Matsuki, Kayo ^a   Tanabe, Atsushi ^b   Hongo, Ayumi ^b   Sugawara, Fumio ^c   Sakaguchi, Kengo ^c   Takahashi, Nobuaki ^a   Sato, Noriyuki ^a   Sahara, Hiroeki ^a,b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AZABU UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' SULFOQUINOVOSYL 1 MONOACYLGLYCEROL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; SHORT HAIRPIN RNA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GLYCOLIPIDS; IMMUNOHISTOCHEMISTRY; MICE; MONOGLYCERIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOSPONDIN 1; TRANSCRIPTOME; UP-REGULATION;

EID: 84864305120     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02333.x     Document Type: Article

References (36)

1. Folkman J. What is the evidence that tumor are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
5. Hurwitz H, Feherenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
7. Bagvandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 1990; 170: 867-72.
8. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
9. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-17.
10. Zang X, Kazerounian S, Duquette M et al. Thrombospondin-1 modulated vascular endothelial growth factor activity at the receptor level. FASEB J 2009; 23: 3368-76.
11. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Robert DD. Thrombospondin-1 inhibit VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010; 285: 38923-32.
12. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999; 3: 147-58.
13. Sahara H, Ishikawa M, Takahashi N et al. In vivo anti-tumour effect of 3′-sulphonoquinovosyl 1′-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 1997; 75: 324-32.
14. Sahara H, Hanashima S, Yamazaki T et al. Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin's natural sulfonoquinovosylmonoacylglycerols. Jpn J Cancer Res 2002; 93: 85-92.
15. Mori Y, Sahara H, Matsumoto K et al. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol (SQMG), targeting angiogenesis. Cancer Sci 2008; 99: 1063-70.
16. Donoviel DB, Framson P, Eldrige CF, Cooke M, Kobayashi S, Bornstein P. Structural analysis and expression of the human thrombospondin gene promoter. J Biol Chem 1988; 263: 18590-3.
17. Isenberg JS, Jia Y, Fukuyama J Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 2007; 282: 15404-15.
18. Isenberg JS, Ridnour LA, Dimitry J et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281: 26069-80.
19. Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem 1999; 274: 24080-6.
20. Isenberg JS, Martin-Manson G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009; 9: 182-94.
21. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-8.
22. Primo L, Ferrandi C, Roca C et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 2005; 19: 1713-5.
23. Kazerounian S, Duquette M, Reyes MA et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood 2011; 117: 4658-66.
24. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010; 285: 38923-32.
25. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
26. Shinobu N, Maeda T, Aso T et al. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem 1999; 274: 17003-10.
27. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395-405.
28. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003; 63: 4698-704.
29. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002; 89: 303-9.
30. Su F, Pascal LE, Xiao W, Wang Z. Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53. Oncogene 2010; 29: 421-31.
31. Alvarez AA, Axelrod JR, Whitaker RS et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001; 82: 273-8.
32. Harada H, Nakagawa K, Saito M et al. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett 2003; 191: 109-19.
33. Tokunaga T, Nakamura M, Oshika Y et al. Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch 1998; 433: 415-8.
34. Dews M, Homayouni A, Yu D et al. Augmentation of tumor angiogenesis by a myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-5.
35. Sundaram P, Hultine S, Smith LM et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011; 71: 7490-501.
36. Kang JH, Kim SA, Chang SY, Hong S, Hong KJ. Inhibition of trichostatin A-induced antiangiogenesis by small-interfering RNA for thrombospondin-1. Exp Mol Med 2007; 39: 402-11.